It would be interesting to see the deal they could get right now. I think they are starting to reach the point where a good deal can be had. Or at least a better deal that we currently have.
One thing I will say is that most biotechs don't get to this level of debt. If they do, I don't see many of them refinance it.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.